222 related articles for article (PubMed ID: 37662962)
1. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
4. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract][Full Text] [Related]
5. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
6. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
[TBL] [Abstract][Full Text] [Related]
7. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
[TBL] [Abstract][Full Text] [Related]
8. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.
Wu L; Deng WW; Huang CF; Bu LL; Yu GT; Mao L; Zhang WF; Liu B; Sun ZJ
Cancer Immunol Immunother; 2017 May; 66(5):627-636. PubMed ID: 28236118
[TBL] [Abstract][Full Text] [Related]
9. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
Lines JL; Sempere LF; Broughton T; Wang L; Noelle R
Cancer Immunol Res; 2014 Jun; 2(6):510-7. PubMed ID: 24894088
[TBL] [Abstract][Full Text] [Related]
10. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
[TBL] [Abstract][Full Text] [Related]
12. H-VISTA Immunohistochemistry Score Is Associated with Advanced Stages in Cutaneous and Ocular Melanoma.
Tinca AC; Szoke AR; Lazar BA; Szász EA; Tomuț AN; Sabău AH; Cocuz IG; Cotoi TC; Niculescu R; Chiorean DM; Ungureanu IA; Turdean SG; Cotoi OS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673920
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
Hou Z; Pan Y; Fei Q; Lin Y; Zhou Y; Liu Y; Guan H; Yu X; Lin X; Lu F; Huang H
J Cancer Res Clin Oncol; 2021 Feb; 147(2):517-531. PubMed ID: 33237432
[TBL] [Abstract][Full Text] [Related]
14. VISTA: Coming of age as a multi-lineage immune checkpoint.
ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
[TBL] [Abstract][Full Text] [Related]
15. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
16. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
17. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
18. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
19. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
